In patients with advanced NSCLC with EGFR T790M, a randomized phase II trial showed a median PFS of 15.8 months for osimertinib monotherapy and 14.6 months for osimertinib and carboplatin-pemetrexed combination therapy, indicating no synergistic effect of combination (Tanaka et al., 2021). Here, EGFR is linked to non-small cell lung carcinoma.